The purpose of the present study was to investigate the association between the monocyte chemoattractant protein-1 (MCP-1) promoter -2518 polymorphism and schizophrenia. One hundred and twenty-three schizophrenic inpatients and 114 healthy controls participated in this study. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism. Genotype and allele distributions in patients with schizophrenia were not significantly different from those of the controls. However, distributions of genotypes and alleles were marginally different when considering subjects with positive and negative symptomatology. The present study therefore calls for further studies on the potential role of the MCP-1 promoter -2518 polymorphism in clinical heterogeneity of schizophrenia.